Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $0Option exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Miller Larry R. | General Counsel | Mar 25 '26 | Option Exercise | $0.00 | 6,920 | $0 | 55,438 | Mar 26 06:07 PM |
Company profile
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Luckshire Daniel J | Executive VP & CFO | Mar 13 '26 | Option Exercise | $0.00 | 11,503 | $0 | 286,567 | Mar 17 04:11 PM |
| Hruby Dennis E | EVP & Chief Scientific Officer | Mar 13 '26 | Option Exercise | $0.00 | 11,445 | $0 | 202,492 | Mar 17 04:09 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.